Longeveron(US:LGVN)2026-03-17 21:32Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $1.2 million, a decrease of $1.2 million or 50% compared to $2.4 million in 2024, primarily due to lower participant demand for clinical trials and reduced contract manufacturing services [10][11] - General and administrative expenses increased to approximately $12 million in 2025 from $10.3 million in 2024, reflecting a 17% increase mainly due to higher personnel costs and a one-time severance cost [11] - Research and development expenses rose to approximately $12 million in 2025 from $8.1 million in 2024, marking a 48% increase driven by personnel costs and CMC costs [12][13] - The net loss increased to approximately $22.7 million in 2025 from $16 million in 2024, a rise of 41% [13] - Cash and cash equivalents as of December 31, 2025, were $4.7 million, with approximately $1.4 million in working capital [14] Business Line Data and Key Metrics Changes - Clinical trial revenue for 2025 was $1 million, down from $1.4 million in 2024, while contract manufacturing revenue decreased from $0.5 million to $0.2 million [10][11] Company Strategy and Development Direction - The company is focused on securing financial resources and efficient capital allocation, having secured $15 million in new capital and the potential for an additional $15 million [2][3] - Strategic partnerships are being pursued to accelerate time to market and leverage resources from larger organizations [3][4] - The company aims to prepare for its first Biologics License Application (BLA) with the U.S. FDA following the results of the ELPIS-II clinical trial [3][4] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position in the stem cell field and the potential for laromestrocel to address significant unmet medical needs [2][15] - The anticipated pivotal data for HLHS and the strengthening of the balance sheet are seen as critical milestones for future growth [17] Other Important Information - The HLHS program has been granted rare pediatric disease designation by the FDA, making it eligible for priority review vouchers (PRVs) upon BLA approval [6] - The company plans to pursue a sale of any PRV received for HLHS, with investors entitled to 50% of the proceeds [6] Q&A Session Summary Question: What are the commercial perspectives regarding scaled-up manufacturing for laromestrocel? - The company is prioritizing manufacturing and CMC, engaging with a CDMO for future manufacturing needs [21][22] Question: What non-dilutive sources of capital could be accessed for Alzheimer's disease and age-related frailty? - The company plans to seek licensing partners for both indications, with preliminary conversations already set up [23] Question: How soon can the BLA for HLHS be filed if data is positive? - The company is potentially eligible for a rolling submission and aims to initiate the regulatory process as quickly as possible after data readout [27][30] Question: What is the timeline for the pediatric dilated cardiomyopathy (PDCM) program? - The goal is to initiate the trial in 2027, with a focus on reducing heart transplant needs through a hierarchical composite endpoint [34][39] Question: What is the strategy for the recently patented use of laromestrocel in female sexual dysfunction? - The company sees this as a high unmet need and is likely to pursue partnerships for development rather than going it alone [45][49]